Slide 1: OraSure 2Q22 Earnings
OraSure 2Q22 Earnings August 9, 2022 EXHIBIT 99.2
Slide 2: Required Disclosures
Required Disclosures This press release contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations, revenue growth, cost savings, cash flow, increasing margins and other matters. Forward-looking statement
Slide 3: 2Q22 Financial Results – Record Revenue and Improved Profitability
2Q22 Financial Results – Record Revenue and Improved Profitability FINANCIAL METRIC 2Q22 RESULTS 1Q22 RESULTS 2Q21 RESULTS SEQUENTIAL GROWTH RATE YEAR-OVER-YEAR GROWTH RATE Quarterly Revenue $80.2 million $67.7 million $57.6 million 18% 39% GAAP EPS / Non-GAAP EPS ($0.26)/($0.00) ($0.28)/($0.15) ($0
Slide 4: Key Elements of Strategic Transformation
Key Elements of Strategic Transformation 2H CY22 CY23 Strengthen CY24 Elevate Accelerate Innovate & operate with disciplined execution & accountability 4
Slide 5: Record Diagnostic Revenue With 95% Sequential Growth in InteliSwab
Record Diagnostic Revenue With 95% Sequential Growth in InteliSwab® FINANCIAL METRIC 2Q22 RESULTS 1Q22 RESULTS 2Q21 RESULTS SEQUENTIAL GROWTH RATE YEAR-OVER-YEAR GROWTH RATE Total Diagnostics $60.4 million $38.3 million $19.3 million 58% 213% InteliSwab® Revenue $43.1 million $22.1 million --- 95% N
Slide 6: Significant Improvements Continue in InteliSwab Production Process
Significant Improvements Continue in InteliSwab® Production Process 14-fold increase in weekly production volume since last year Gross margins for InteliSwab® increase 2,000+ basis points sequentially Current production capacity of 1.6M tests per week … plans to double capacity in 2023 STILL TO COME
Slide 7: US Government Continues Support for InteliSwab
US Government Continues Support for InteliSwab® Continued Procurement as part of OraSure’s Defense Logistics Agency/HHS contract Consistent ongoing testing needed in congregate settings Evens out demand, enables shipments even during low points between surges
Slide 8: Molecular Solutions Revenue In Line With Expectations
Molecular Solutions Revenue In Line With Expectations FINANCIAL METRIC 2Q22 RESULTS 1Q22 RESULTS 2Q21 RESULTS SEQUENTIAL GROWTH RATE YEAR-OVER-YEAR GROWTH RATE Core Molecular Kits $17.3 million $21.9 million $17.1 million 1% (21%) COVID-19 Collection Kits $0.3 million $12.0 million $8.9 million NM N
Slide 9: Enabling Multi-Omic Discovery and Diagnostics Through Innovation
Meta-transcriptome launch FDA clearance for gut kit Enabling Multi-Omic Discovery and Diagnostics Through Innovation Launch of RNA/DNA kit Continued evidence supporting urine- based STI testing
Slide 10: Molecular Solutions COVID-19 Kit Revenue
Molecular Solutions COVID-19 Kit Revenue Increasing transition from central lab testing to POC testing options
Slide 11: Consolidated Revenue by Quarter
Consolidated Revenue by Quarter Revenue (in mil.) Record Revenue in 2Q22 … 39% YoY Growth Record revenue in 2Q22 39% YoY growth
Slide 12: Financial Results
Financial Results ‘Daee Mens Ended ume 3, FT} 70a Rents of Operstions ‘Netrevanes 3 s021 57607 Coster moiucts md saves soll 5,687 25934 Gross oft 27,584 30673 Operating expences: Reseuch mud develogment 9.68 1692 Subs and muketng ries 10420 Genersland admaisratae isi 1n993 Goodland bng ved assts iup
Slide 13: 3Q22 Financial Guidance
3Q22 Financial Guidance GUIDANCE METRIC FINANCIAL GUIDANCE 3Q22 Total Revenue $90 - $95 million 3Q22 Gross Margins Continued improvement from 2Q22 3Q22 Cash Utilization Continued improvement from 2Q22
Slide 14: Summary
Summary Momentum in strategic transformation … innovating and operating with disciplined execution and accountability Significant improvements achieved in InteliSwab® production and manufacturing efficiency … 2,000+ basis point sequential increase in InteliSwab® gross margins Neutral non-GAAP net in
Slide 15: Q&A
Q&A OraSure Technologies oNAgenoTeK” Diversigen’ Wnovosanis